Blincyto (Blinatumomab) Medicine
Generic name : Blinatumomab.
Trade name : Blincyto.
Manufacturer information :
Blincyto is manufactured by Amgen Inc.
Blincyto FDA Approval:
Blincyto first approved December 3rd, 2014.
Dosage form :
For injection: 35 mcg of lyophilized powder in a single-use vial for reconstitution.
Blincyto Indications and Usage :
Acute Lymphoblastic Leukemia
Indicated for Philadelphia chromosome-negative relapsed or refractory B cell precursor acute lymphoblastic leukemia (ALL).
Blincyto (Blinatumomab) availability in India
- You could import this medicine against import permit on Patient Name.
- Please contact ACT Lifesciences Private Limited for further information.